Medidata Launches Programs to Address Two Critical Social Needs: Advancing Patient Access to Treatments and Increasing Student Participation in STEM Education

Social Innovation Lab, Founders’ Scholarship, and MediEd - New Additions to Medidata’s Corporate Social Responsibility Programs

NEW YORK, NY – December 4, 2019Medidata, the global leader in creating end-to-end solutions supporting the entire clinical trial process, and a Dassault Systèmes company, announced three new social impact initiatives within its expanding corporate social responsibility (CSR) program: Social Innovation Lab, Founders’ Scholarship, and MediEd. These programs are designed to make a difference in the lives of patients and researchers and are part of Medidata’s mission to power smarter treatments and healthier people.

Social Innovation Lab: Medidata employee volunteers participate in cross-functional teams to support non-profit partners with programs that expand patient access to treatment. These efforts include:

  • The Castleman Disease Collaborative Network and the Castleman Disease Center for Excellence at the University of Pennsylvania - working to optimize organizational synergies, digital communications, and data utilization to accelerate the discovery of treatments
  • Cures Within Reach - creating a more user-friendly experience on their CureAcceleratorTM platform, which connects researchers, funders, and industry and patient groups, to help expand the number of users and reach into the developing world
  • The Lazarex Cancer Foundation - creating a data-driven analysis of key cancer centers across the United States to support the expanded Foundation IMPACT program, which helps increase patient diversity in clinical trials and provides assistance for out-of-pocket costs

“The collaboration with Medidata is a game changer for us, vastly expanding the limited resources of Lazarex to complete research projects that are well beyond the scope of what we can accomplish on our own,” said Dana Dornsife, founder and board chair, Lazarex. “The Medidata results are vital for us to make evidence-based decisions, elevating us from trial and error efforts to taking strategic and precise program actions.”

Founders’ Scholarship: In honor of Medidata’s 20th Anniversary, the Founders Scholarship program will provide a $20,000 scholarship in support of a junior or senior college student pursuing a STEM education. The recipient will also receive an internship at Medidata’s headquarters in New York City during the summer of 2020. Scholarship criteria include grade point average, financial need, extracurricular activities and community involvement.

MediEd: MediEd helps students prepare for careers in the life sciences industry by providing them with practical experience in key competencies for data management and informatics, study and site management, and ethical considerations for clinical trials. Medidata is donating its Rave EDC (electronic data capture) software to selected universities to capture, cleanse, and manage study data across every phase of the clinical trial life cycle. The partnership started with the University of North Carolina at Wilmington, and has now expanded to include Durham Technical Community College and Campbell University. 

“At Medidata, we are committed to leveraging our expertise in life sciences and technology to have a positive impact on patients and students,” said Tarek Sherif, co-CEO and co-founder, Medidata. “These three programs exemplify our commitment to powering a future where everyone has access to treatment and education.”

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata,

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit https://www.3ds.com